Blog

Lauren Brown: Another insightful article out of the AURORA collaboration

Photo taken from www.clinical-lung-cancer.com

May 10, 2024, 14:58

Lauren Brown: Another insightful article out of the AURORA collaboration

Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical Oncology Fellow at Westmead and Blacktown Hospitals, made the following post on X:

“Another insightful article out of the AURORA collaboration. Patients with KRAS, or PDL1 ≥50% are more likely to complete 24-months of pembro for NSCLC. Patients with oligoprogression in the brain treated with RT can still have enduring responses.”

Read the article.
Source: Lauren Brown/X

AURORA collaboration Blacktown Hospital brain metastases cancer cancer treatment KRAS mutation Lauren Brown Medical Oncology Fellow Medical Research NSCLC oligoprogression OncoDaily Oncology PD-L1 pembrolizumab PhD Candidate radiotherapy Research University of Sydney Westmead Hospital Westmead Institute for Medical Research

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 9

Shannon Miller and Ovarian Cancer: How She Went Against, How She Survived, and More

ASTRO Overview: Everything You Need to Know About the Leading Radiation Oncology Society

Kamala Harris vs Donald Trump on Cancer: From Cancer Moonshot to Right to Act, Funding, Research and Future

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

Special Coverage